Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 8, 2019

 

 

Kaleido Biosciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38822   47-3048279

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

65 Hayden Avenue

Lexington, MA

  02421
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 674-9000

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 7.01.

Regulation FD Disclosure.

Kaleido Biosciences, Inc. (the “Company”) is furnishing a corporate presentation, attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company intends to use from time to time in meetings with investors and others beginning on April 8, 2019. The corporate presentation will also be available in the investor relations section of the Company’s website at http://kaleido.com.

The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

    No.    

  

Description

99.1    Kaleido Biosciences, Inc., corporate presentation.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 8, 2019     KALEIDO BIOSCIENCES, INC.
    By:  

/s/ Alison Lawton

      Alison Lawton
      Chief Executive Officer
EX-99.1

Slide 1

APRIL 2019 Company Overview Exhibit 99.1


Slide 2

Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the anticipated use of our existing cash resources, including proceeds from our initial public offering, the duration for which our existing capital resources will fund our operations, statements regarding the therapeutic potential of our Microbiome Metabolic Therapy (MMT) candidates and our strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this presentation are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this presentation, including, without limitation, those related to the planned Phase 2 clinical trial for KB195 for the treatment of UCD, including timeline for initiation, completion and reporting of results, the preclinical and clinical development and safety profile of our MMT candidates and timelines associated with the programs for such MMT candidates, whether and when, if at all, our MMT candidates will receive approval from the U.S. Food and Drug Administration or other applicable regulatory agencies, if any, competition from other biotechnology companies, and other risks identified in our SEC filings, including our final prospectus for our initial public offering, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this presentation represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.


Slide 3

The 1st Company to Use a Chemistry-Driven Approach Intended to Systematically Drive FUNCTIONAL OUTPUTS OF THE MICROBIOME ORGAN Translating the Promise of the Microbiome Into Solutions for Patients


Slide 4

The Kaleido Opportunity Proprietary Product Platform Broad Pipeline with Large Market Opportunity Faster, More Cost Efficient Model Significant Computational Biology and Data Science Capabilities Enable Kaleido to Learn MORE, and Learn FASTER Human-Centric Discovery & Development World-Class Leadership Team


Slide 5

Built A World-Class Leadership Team Alison Lawton President & Chief Executive Officer Former GM, Genzyme Biosurgery, COO Aura & OvaScience Josh Brumm Chief Operating Officer, Chief Financial Officer Former COO & CFO, Versartis, EVP Finance, Pharmacyclics & CFO, ZELTIQ Kate Knobil, M.D. Chief Medical Officer, Head of R&D Former CMO at GlaxoSmithKline Johan van Hylckama Vlieg, Ph.D. Chief Scientific Officer (as of July 1st)1 Former VP for Microbiome & Human Health Innovation, Chr. Hansen Clare Fisher Chief Business Officer Former Group VP, Global Head of Transactions & Business Development, Shire Mike Bruce, Ph.D. SVP, Development Operations Former SVP Program, Portfolio & Alliance, CRISPR, VP, Development Operations, Pfizer Sue Stewart, J.D. SVP, Regulatory & Compliance Former SVP, Regulatory Affairs, Quality, and Compliance, Tokai Pharmaceuticals Stephen Sofen, Ph.D. SVP, Technical Operations Former VP, Technical Operations, CRISPR Mike Bonney Executive Chair Former CEO, Cubist Pharmaceuticals COMPANY BUILDING THERAPEUTIC AREA BREADTH & TECHNOLOGY DEPTH CLINICAL DEVELOPMENT & REGULATORY MANUFACTURING Note(s): 1. Dr. van Hylckama Vlieg is serving as a scientific advisor and consultant to Kaleido until he assumes the role of CSO on July 1, 2019.


Slide 6

Founded Company in 2015 to Create a New Category of Drugs and Health Products Significant Accomplishments Since Founding 1,000+ MMT candidates in our library today IND Cleared, Phase 2 clinical trial initiation planned for 1H 2019 7 non-IND human clinical studies conducted with our Microbiome Metabolic Therapy (MMT™) candidates 5 current pipeline programs in multiple disease areas 100+ non-provisional applications world-wide in 20+ regions/countries, 8 US patents, 2 EPO patents $75M IPO in February 2019


Slide 7

PROGRAM Target Mechanism of Action Ex Vivo Screening Ex Vivo Testing Healthy Volunteers Patients Potential IND Filing2 Phase 13 Phase 2 Phase 3 Hyperammonemia: Urea Cycle Disorders (KB195) Ammonia N/A4 1H’19 Hyperammonemia: Hepatic Encephalopathy (KB174 or KB195) Ammonia 1H’20 2H’20 Infections Caused by Multi-Drug Resistant Bacteria (KB109) MDR Pathogens 1H’19 Atherosclerotic Cardiovascular Disease TMA Chronic Kidney Disease Uremic Toxins Non-IND Human Clinical Studies1 Note(s): In our non-IND human clinical studies, we evaluate the safety, tolerability and markers of effect of our MMT candidates in human subjects. For MMT candidates pursuing a drug development pathway an IND will be filed; for those that we elect to continue on a non-drug development pathway, INDs will not be required. Based on our experience with UCD, we believe we may be able to advance other MMT candidates directly into Phase 2. Based on feedback from the FDA and clearance of our IND for KB195 in UCD, we are advancing directly into a Phase 2 trial. Dates represent initiation of human dosing or submission of IND filing. In Progress Completed Mechanism of Action Decrease Production of Metabolites Advantage/Disadvantage Certain Species Broad Pipeline Pipeline progressed in ~4 years, spending less than $92M in cash through Dec. 2018 Potential to generate 1-2 Phase 2 ready INDs per year


Slide 8

The Microbiome Organ Has the Potential to Address a Broad Range of Diseases The Microbiome is Implicated in Numerous Conditions Obesity Type 2 Diabetes Parkinson’s Disease Short-Chain Fatty Acids (SCFAs) Urea Cycle Disorders Hepatic Encephalopathy Nitrogen Metabolism Chronic Kidney Disease Organic Acidemias Phenylketonuria (PKU) Amino Acids Asthma IBD Multiple Sclerosis Direct Immune Modulators Bile Acids Primary Sclerosing Cholangitis (PSC) NASH Indigenous Bacteria from Gut Microbiota Regulate Host Serotonin Biosynthesis Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota The severity of NAFLD is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models Microbiota Modulate Behavioral and Physiological Abnormalities Associated with Neurodevelopment Disorders Human nutrition, the gut microbiome and the immune system Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients An obesity-associated gut microbiome with increased capacity for energy harvest Glycans Are Known to Drive Metabolic Shifts that Have an Impact on Host Physiology


Slide 9

We’re Leveraging 10 Years of Scientific Insights and Knowledge Computational Capabilities Automation & Miniaturization Rapid, human-relevant screening Powerful Enabling Tools Are Available Now Is the Time to Develop Targeted Therapies for the Microbiome Organ Shallow Shotgun Sequencing 16S RNA Sequencing Metabolomics 2010s 2000s 1990s 1980s Discovery of microbes 1890 Koch’s postulates More microbes than human cells Microbiome structure revealed $115M Human Microbiome Project launched Number of papers Growing Body of Research


Slide 10

FOCUS KNOWLEDGE OVER TIME Functions of the Microbiome Composition of the Microbiome Subtract Bacteria “Kill the bugs” (e.g. Antibiotics) Add Bacteria “Bugs as drugs” (e.g. fecal microbiota transplants, bacterial therapy) Drive Existing Bacteria Microbiome Metabolic Therapies, or MMTs (i.e. targeted glycans) Unique Chemistries that Can Drive the Functional Output of the Microbiome We Have a Unique and More Evolved Approach


Slide 11

Our Microbiome Metabolic Therapies (MMT™) Are Proprietary, Novel Compounds CHARACTERISTICS ADVANTAGES Initial MMTs are targeted glycans Drivers of gut metabolism, long history of safe human consumption Related to a class of compounds that is Generally Recognized As Safe (GRAS) Ability to advance rapidly into the clinic; flexibility to develop as therapeutics, food or medical food Limited systemic exposure Potentially minimizes off-target biological effects Highly soluble Can be orally administered Novel and proprietary Robust IP portfolio


Slide 12

Our MMTs Are Designed to Work Through One or More Mechanisms of Action, Including ... DECREASE Production of Metabolites INCREASE Production of Metabolites ADVANTAGE or DISADVANTAGE Certain Species in the Microbiome Community


Slide 13

Human-Centric Discovery & Development EX VIVO SCREENING IN HEALTHY MICROBIOME SAMPLES 1 EX VIVO TESTING IN PATIENT MICROBIOME SAMPLES 2 RAPID ADVANCEMENT INTO NON-IND HUMAN CLINICAL STUDIES 3 Patients Healthy Volunteers & Data Collected at Every Stage to Leverage Computation Capability Human Data Drives Learning and MMT Optimization MMT DECISION POINT File IND and Proceed to Phase 2 Pursue Non-Drug Development Pathway/Commercialization


Slide 14

Faster, More Cost Efficient Model Note(s): 1. To date with respect to KB195, which we have decided to develop as a drug candidate 2. DiMasi, Joseph, et. al: Innovation in the pharmaceutical industry: New estimates of R&D costs, Journal of Health Economics, 2016, 47, 20-23. Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Kaleido’s Discovery and Development1 <3 Years Study of Traditional Pharmaceutical R&D2 5-7 Years Discovery 1 Year Non-IND Human Clinical Studies 2 Years Phase 1 ~1.5 Years IND Start Phase 2 Start Phase 2 Discovery, Preclinical ~5 Years Kaleido IND1 Discovery (human ex vivo) Abbreviated preclinical data Scale for Phase 2 Human clinical safety, tolerability Dose-response Biomarkers may also be a surrogate for efficacy Start Phase 2 Start Phase 1 Traditional IND Discovery Data Animal Data Scale to Phase 1 IND


Slide 15

PROGRAM Target Mechanism of Action Ex Vivo Screening Ex Vivo Testing Healthy Volunteers Patients Potential IND Filing2 Phase 13 Phase 2 Phase 3 Hyperammonemia: Urea Cycle Disorders (KB195) Ammonia N/A4 1H’19 Hyperammonemia: Hepatic Encephalopathy (KB174 or KB195) Ammonia 1H’20 2H’20 Infections Caused by Multi-Drug Resistant Bacteria (KB109) MDR Pathogens 1H’19 Atherosclerotic Cardiovascular Disease TMA Chronic Kidney Disease Uremic Toxins Non-IND Human Clinical Studies1 Note(s): In our non-IND human clinical studies, we evaluate the safety, tolerability and markers of effect of our MMT candidates in human subjects. For MMT candidates pursuing a drug development pathway an IND will be filed; for those that we elect to continue on a non-drug development pathway, INDs will not be required. Based on our experience with UCD, we believe we may be able to advance other MMT candidates directly into Phase 2. Based on feedback from the FDA and clearance of our IND for KB195 in UCD, we are advancing directly into a Phase 2 trial. Dates represent initiation of human dosing or submission of IND filing. In Progress Completed Mechanism of Action Decrease Production of Metabolites Advantage/Disadvantage Certain Species Broad Pipeline


Slide 16

BRAIN Main Site of Ammonia Toxicity GUT Ammonia Production LIVER Main Site of Ammonia Clearance The Hyperammonemia Opportunity Sources: Batshaw, M. L., et. al. (2014). A longitudinal study of urea cycle disorders, Molecular Genetics and Metabolism, 113(0), 127-130; Montgomery, J. Y., & Bajaj, J. S. (2011). Advances in the Evaluation and Management of Minimal Hepatic Encephalopathy, Current Gastroenterology Reports, 13, 26-33; Company reports KB174 / KB195 Hepatic Encephalopathy (HE) Neuropsychiatric abnormalities in patients with liver dysfunction ~500,000 patients in U.S., many have not been diagnosed Two current approved treatments for Overt HE (OHE) High Unmet Medical Need No current approved treatment for Minimal HE (MHE) Reduce OHE episodes and infection risk More tolerable therapy POTENTIAL CLINICAL ENDPOINTS: Time to first breakthrough OHE episode KB195 Urea Cycle Disorders (UCD) Inability to convert ammonia due to inborn urea cycle defects Orphan disease with ~3,000 patients in U.S. High unmet medical need despite available treatments Reduce the Risk of Life-Threatening Crises POTENTIAL CLINICAL ENDPOINTS: Reduction in serum ammonia 24-hour area under the curve


Slide 17

Ex Vivo Screening: KB195 Reduced Ammonia in Healthy Microbiomes Ability to Screen Many MMTs Across Our Compound Library for Ability to Reduce Ammonia Compound Ammonia Levels Normalized to Control 1 KB195 Lead MMT Reduced Ammonia by 97%, Compared to Control (water) 97% Control Ammonia Levels Normalized to Control KB195 Control


Slide 18

2 KB195 in Hepatically Impaired Patients Ex Vivo Testing: KB195 Reduced Ammonia in Patient Microbiomes KB195 in UCD Patients Reduced Ammonia in All Microbiome Samples Reduced Ammonia by > 50% in 10 Out of 12 Samples Reduced Ammonia in 18 of 19 Microbiome Samples Outperformed Lactulose in Reducing Ammonia Levels in 14 of 19 Samples Ammonia Reduction Relative to Control (%) Ammonia Reduction Relative to Control (%)


Slide 19

3 Randomized, controlled, double-blind study in healthy subjects on a high protein diet KB195 Significantly Lowered Nitrogen 40.5% Decrease in Urinary 15N Excretion Compared to Negative Control (p=0.0126) Non-IND Human Clinical Studies: KB195 Note(s): 1. De Preter V. et al., Alimentary Pharmacology & Therapeutics 23, 963-974 (2006) 2. The study also included an additional comparator glycan arm. Operational challenges resulted in interruptions in the dosing schedule and as such, the incomplete comparator glycan arm data are not reported here.   Lactulose ~20% reduction1 Urine 15N Excreted; % Change from Baseline Negative control KB195 Comparator glycan2 Results from 72 g/day dose KB195 Observed to Have A Significant Effect on Ammonia Reduction n=11 n=12 n=12


Slide 20

Non-IND Human Clinical Studies: KB195 Fewer Subjects Receiving KB195 Reported Diarrhea3 1 3 18g/day 1 4 36g/day 1 6 54g/day 4 10 72g/day 1 1 3 4 Negative control KB195 Comparator glycan Dosing Period Lactulose ~20% reduction1 Urine 15N Excreted; % Change from Baseline Results from 72 g/day dose KB195 Observed to Have A Significant Effect on Ammonia Reduction Note(s): 1. De Preter V. et al., Alimentary Pharmacology & Therapeutics 23, 963-974 (2006) 2. The study also included an additional comparator glycan arm. Operational challenges resulted in interruptions in the dosing schedule and as such, the incomplete comparator glycan arm data are not reported here. 3. Based on Bristol Stool Score 3 n=11 n=12 n=12 Negative control KB195 Comparator glycan2


Slide 21

Our Additional Programs Focus on Multiple Indications DECREASE Production of Metabolites TMA Atherosclerotic Cardiovascular Disease (ASCVD) No Marketed Prescription Treatments That Address Elevated Levels of TMAO in Treatment of ASCVD Uremic Toxins Chronic Kidney Disease Significant Prevalence & Cost Burden to Healthcare System INCREASE Production of Metabolites Short Chain Fatty Acids ADVANTAGE or DISADVANTAGE Certain Species in the Microbiome Community MDR Pathogens Liver Transplant Patients Hematopoietic Stem Cell Transplantation (HSCT) Patients A Serious Threat


Slide 22

Ex Vivo Testing Our MMTs Observed to Reduce Pathogens by a Median of 45% Relative to Control in 10 of 13 Samples Microbiome Samples from 13 ICU Patients Pathogen Reduction Relative to Control (%) Hours % Pathogen MMTs for Infections Caused by Multi-Drug Resistant Bacteria Ex Vivo Screening Our MMTs Observed to Reduce Pathogens


Slide 23

Ex Vivo Screening: Top MMTs Reduced TMA in Healthy Microbiomes Our top MMTs reduced TMA by >90% in Ex Vivo Screening Compared To Control Conducted high-throughput MMT screening to identify hits Top leads will be tested ex vivo in microbiomes of patients with cardiovascular disease Following ex vivo testing, plan to conduct a non-IND clinical study Control


Slide 24

Lead Programs in Hyperammonemia Demonstrate the Power of Our Proprietary Product Platform Note(s): 1. As evidenced by lowered urinary15N excretion in the non-IND clinical study of KB195 in healthy subjects Pathologies that Result in an Excess of Ammonia in the Blood Decrease Production of Ammonia Significant Unmet Medical Need CLINICAL Reduced ammonia levels in ex vivo testing of patient microbiome samples First Non-IND Human Clinical Study Lowered Net Ammonia Production1 Observed Ammonia Reductions Across Heterogeneous Microbiomes Non-IND clinical study in UCD patients is ongoing SPEED & COST EFFICIENCY VALIDATED Two MMTs advancing in two hyperammonemia indications Plan to initiate Phase 2 clinical trial ~24 months after having conducted our first ex vivo screen BROAD APPLICABILITY LEVERAGED ACROSS PIPELINE FDA FEEDBACK ON UCD IND cleared and advancing directly into a Phase 2 clinical trial planned for 1H 2019 Our compound is novel and unique Hyperammonemia Urea Cycle Disorders (UCD) Hepatic Encephalopathy (HE) FDA


Slide 25

Large Market Opportunity Across Diseases UCD HE ~3,000 patients in the U.S. Current treatment (Ravicti) costs $800K/year in the U.S. ~40% of patients on Ravicti have high ammonia levels and remain at risk ~500K patients in the U.S., not all of whom have been diagnosed (100K OHE, 400K MHE) Only 1/3rd of OHE patients treated with Xifaxan; no treatment for MHE Xifaxan annual sales for OHE ~$650M in U.S. Atherosclerotic Cardiovascular Disease ~30 million adults diagnosed with heart disease in the U.S. Heart disease is the leading cause of death in the U.S. (25% of deaths) Existing treatments aimed at addressing known risk factors Infections Caused by MDR Bacteria ~2 million people annually in the U.S. infected with bacteria resistant to antibiotics Liver Transplant ~13K candidates waiting in the U.S. 50% of patients develop an infection in the first 100 days post-transplant Hematopoietic Stem Cell Transplantation(HSCT) ~22K patients in the U.S. each year ~1/3 are colonized with VRE Potential Worldwide Market Opportunity1 ~$2B+ Multi-billion dollar $500M+ ~$300-$500M Note(s): 1. Company estimates


Slide 26

High Quality, Consistent, and Scalable Manufacturing in Place Internal Manufacturing Production for ex vivo, toxicology, and human clinical studies 3rd Party Manufacturers Production of larger quantities of our MMT candidates for clinical trials and future commercial supply (Thermo Fisher Scientific) Expertise and Proprietary Manufacturing Methods that Are Scalable and Transferable Uses Standard Small Molecule Unit Operations Robust Analytical Methods to Assess the Identity and Purity of Our MMTs Ability to Produce Bulk MMTs Suitable for Oral Administration in a Variety of Forms (e.g. Liquids, Spray Dried Powders in Sachets)


Slide 27

Robust Global IP Portfolio 8 U.S. Patents + 2 EPO Patents: Glycan pharmaceutical compositions (Europe) Methods to reduce ammonia (U.S.) Methods to treat diarrhea (U.S.) Methods to treat dysbiosis (U.S.) Catalyst compositions (U.S. and Europe) 100+ Non-Provisional Applications Pending, Worldwide in 20+ Regions/Countries Glycan compositions Methods to treat pathogen colonization Methods to treat immune imbalances (e.g. cancer) Methods to modulate short chain fatty acids Methods of making glycans Continued IP Expansion by Filing Patent Applications Directed to Pharmaceutical Compositions, Methods of Treatment and Methods of Manufacture


Slide 28

Financial Overview1 $76M (as of 12/31/18) $54M (for the year ended 12/31/18) $15M (as of 12/31/18) Cash and Cash Equivalents Operating Expenses (2) Long Term Debt Note(s): 1. Numbers are rounded to nearest million 2. Excludes stock-based compensation


Slide 29

Executing Towards our Key Milestones UCD HE Infections Caused by MDR Bacteria TMA Non-IND clinical study in patients Non-IND clinical study in patients with cirrhosis Non-IND clinical study Initiate non-IND clinical study 2019 1H 2H 2020 1H 2H Phase 2 clinical trial Data expected Non-IND clinical study in healthy volunteers to explore dosing Ready to initiate Phase 2 trial Discovery engines to drive new MMTs for add’l non-IND clinical studies and to generate 1-2 Phase 2 ready programs Platform 2021+


Slide 30

The Kaleido Opportunity Expanding number of proprietary MMTs, IP, computational capabilities Multiple indications and MOAs targeting unmet patient needs in significant markets; non-IND human clinical studies completed and ongoing Demonstrated speed and cost efficiency to the clinic Enables rapid advancement of broad portfolio of MMTs by learning more and faster from human data Extensive experience, including company building, product development and manufacturing across many technologies and therapeutic areas PLATFORM PIPELINE MODEL HUMAN-CENTRIC TEAM


Slide 31